Mereo BioPharma (MREO) Enterprise Value (2019 - 2026)

Mereo BioPharma (MREO) has reported Enterprise Value for 8 consecutive years, with $21.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value fell 94.4% year-over-year to $21.0 million in Q2 2026; TTM through Jun 2026 was $21.0 million, a 94.4% decrease from a year earlier, with the FY2025 full-year figure at $25.5 million, down 94.76% from the prior year.
• Enterprise Value was $21.0 million for Q2 2026 at Mereo BioPharma, down from $22.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at $557.1 million in Q3 2024 and troughed at $21.0 million in Q2 2026.
• A 5-year average of $228.6 million and a median of $223.7 million in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 863.63% in 2023 and plunged 94.76% in 2025, its largest moves.
• Over 5 years, Enterprise Value stood at $27.7 million in 2022, then surged by 863.63% to $266.6 million in 2023, then jumped by 82.58% to $486.7 million in 2024, then sank by 94.76% to $25.5 million in 2025, then fell by 17.78% to $21.0 million in 2026.
• The last three Enterprise Value figures came in at $21.0 million (Q2 2026), $22.6 million (Q1 2026), and $25.5 million (Q4 2025), per Business Quant data.